`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`Palo Alto Networks, Inc. and
`Blue Coat Systems, Inc.,
`Petitioners
`
`v.
`
`Finjan, Inc.
`Patent Owner
`
`Inter Partes Review No. 2015-019741
`U.S. Patent No. 7,647,633
`
`PETITIONER’S REPLY IN SUPPORT OF ITS
`MOTION TO EXCLUDE EVIDENCE UNDER 37 C.F.R. § 42.64(c)
`
`
`
`
`
`
`
`
`
`
`
`
`
`1 Case IPR2016-00480 has been joined with this proceeding.
`
`
`
`Table of Contents
`
`
`Page
`
`
`I.
`
`II.
`
`PARAGRAPH 57 OF THE GOODRICH DECLARATION IS
`INADMISSIBLE ............................................................................................ 1
`PARAGRAPHS 13-27, 30-34 OF THE BIMS DECLARATION ARE
`INADMISSIBLE ............................................................................................ 1
`III. BLUE COAT VERDICT FORM (EX. 2004) ................................................ 3
`IV. BLUE COAT TRIAL ARGUMENTS AND TESTIMONY (EXS.
`2018, 2007, 2027) AND BLUE COAT TRIAL EXHIBITS (EXS.
`2012, 2014, 2016) ........................................................................................... 3
`BLUE COAT CLAIM CHART (EX. 2048) .................................................. 4
`V.
`VI. SECURE COMPUTING MATERIALS (EXS. 2037, 2029) &
`ORDER (EX. 2028) ........................................................................................ 5
`
`
`
`
`
`
`
`-i-
`
`
`
`
`
`Table of Authorities
`
`
`Page
`
`
`Cases
`Apple, Inc. v. Ameranth, Inc.,
`CBM2015-00080, Paper 44 (PTAB Aug. 26, 2016) ............................................ 1
`Blonder-Tongue Labs., Inc. v. Univ. of Ill. Found.,
`402 U.S. 313 (1971) .............................................................................................. 3
`Brose North Am. v. UUSI, LLC,
`IPR2014-00417, Paper 49 (PTAB July 20, 2015) ................................................ 4
`Goldberg v. Kelly,
`397 U.S. 254 (1970) .............................................................................................. 3
`Graftech Int’l Holdings v. Laird Techs.,
`652 Fed. Appx. 973 (Fed. Cir. 2016) .................................................................... 2
`IBM Corp. v. Intellectual Ventures II LLC,
`IPR2015-00092, Paper 44 (PTAB Apr. 25, 2016) ............................................... 2
`InTouch Techs. v. VGo Communs., Inc.,
`751 F.3d 1327 (Fed. Cir. 2014) ............................................................................ 1
`Iron Grip v. USA Sports,
`392 F.3d 1317 (Fed. Cir. 2004) ............................................................................ 3
`Smith & Nephew, Inc. v. Bonutti Skeletal Innovations LLC,
`IPR2013-00629, Paper 18 (PTAB June 30, 2014) ............................................... 4
`St. Jude Med. v. Bd. of Regents of Univ. of Mich.
`IPR2013-00041, Paper 69 (PTAB May 1, 2014) ................................................. 5
`Standard Innovation Corp. v. Lelo, Inc.,
`IPR2014-00148, Paper 41 (PTAB Apr. 23, 2015) ............................................... 3
`Warner-Jenkinson Co. v. Hilton David Chem. Co.,
`520 U.S. 17 (1997) ................................................................................................ 3
`
`
`
`-ii-
`
`
`
`Table of Authorities
`(continued)
`
`Page
`
`
`Statutes
`5 U.S.C. § 554 ............................................................................................................ 3
`Other Authorities
`F.R.E.
`402 ......................................................................................................................... 5
`403 ......................................................................................................................... 5
`702 ......................................................................................................................... 1
`703 ............................................................................................................. 1, 2, 4, 5
`801(d)(2) ............................................................................................................... 3
`803(8) ................................................................................................................ 4, 5
`
`
`
`
`
`-iii-
`
`
`
`Petitioner’s Reply
`IPR2015-01974
`
`
`
`I.
`
`PARAGRAPH 57 OF THE GOODRICH DECLARATION IS INADMISSIBLE
`Finjan’s assertion that “Petitioner failed to object to the admissibility of
`
`paragraph 57” (Paper 40 at 1-2) is false. PAN objected to Dr. Goodrich’s opinions
`
`as conclusory and unreliable under FRE 702-703, and specifically cited ¶ 57 as an
`
`example because of its reliance on the Bims Declaration. (Paper 23 at 2-3.)
`
`Finjan does not dispute that Dr. Goodrich failed to review any Finjan
`
`licenses, analyze any products to determine whether they practice the challenged
`
`claims, or provide any evidence or analysis concerning nexus. (See Paper 40 at 2-
`
`3.) Instead, Finjan merely asserts that Dr. Goodrich “independently” reviewed the
`
`Bims Declaration and concluded that secondary considerations are “relevant.” (Id.
`
`at 2.) But merely reviewing and agreeing with another’s opinions does not yield
`
`reliable or helpful expert testimony. See Apple, Inc. v. Ameranth, Inc., CBM2015-
`
`00080, Paper 44 at 39 (PTAB Aug. 26, 2016).
`
`Finjan also does not dispute that Dr. Goodrich based his copying opinions
`
`only on knowledge of Finjan’s patents and desire to compete. Those opinions
`
`should be excluded because they rely on an incorrect legal standard. See InTouch
`
`Techs. v. VGo Communs., Inc., 751 F.3d 1327, 1348 (Fed. Cir. 2014).
`
`II.
`
`PARAGRAPHS 13-27, 30-34 OF THE BIMS DECLARATION ARE INADMISSIBLE
`Finjan’s suggestion that PAN waived its objections to Dr. Bims’s testimony
`
`(Paper 40 at 3) is baseless. PAN objected to Dr. Bims’s opinions under FRE 702-
`
`
`
`1
`
`
`
`Petitioner’s Reply
`IPR2015-01974
`
`
`703 because they “are conclusory, do not disclose supporting facts or data, and/or
`
`are based on unreliable facts, data, or methods.” (Paper 23 at 3.) As one of multiple
`
`examples, Petitioner identified Dr. Bims’s opinions that certain licensee products
`
`allegedly practice the challenged claims, which relate directly to Dr. Bims’s failure
`
`to provide evidence of nexus between the challenged claims and any evidence of
`
`licensing, copying, and long-felt need. (Ex. 2020 at ¶¶ 13-27, 30-34.) And unlike in
`
`IBM Corp. v. Intellectual Ventures II LLC, IPR2015-00092, Paper 44 at 55 (PTAB
`
`Apr. 25, 2016), where the patent owner completely changed its relevance objection
`
`by asserting that the reference was not prior art, PAN’s initial objection identified
`
`both its general objections and a particular example of the same deficiency that is
`
`the subject of its motion to exclude. (Paper 35 at 4-8.)
`
`Finjan does not dispute that Dr. Bims failed to review Finjan licenses, based
`
`his copying opinions only on alleged knowledge of Finjan’s products and a desire
`
`to compete, and failed to identify a problem or evidence of efforts to solve that
`
`problem. (Paper 35 at 4-8; Paper 40 at 2-3.) Finjan argues only that Dr. Bims
`
`“analyze[d] the benefits of the patented technology to [third party] products and
`
`revenues that these third parties make publicly available.” (Paper 40 at 3.) And Dr.
`
`Bims admitted that his analysis did not tie any alleged benefits or revenues to the
`
`challenged claims (Ex. 1098 at 37:22-39:22, 40:3-17), contrary to law. Graftech
`
`Int’l Holdings v. Laird Techs., 652 Fed. Appx. 973, 978-79 (Fed. Cir. 2016).
`2
`
`
`
`
`
`Petitioner’s Reply
`IPR2015-01974
`
`III. BLUE COAT VERDICT FORM (EX. 2004)
`Infringement—under the doctrine of equivalents or otherwise—is not the
`
`
`
`equivalent of copying, Iron Grip v. USA Sports, 392 F.3d 1317, 1325 (Fed. Cir.
`
`2004), and an infringement verdict does not indicate the jury even considered
`
`copying. Warner-Jenkinson Co. v. Hilton David Chem. Co., 520 U.S. 17, 35-36
`
`(1997). Similarly, the Blue Coat jury’s validity determination was based on a prior
`
`art reference not at issue in—and thus not relevant to—this proceeding.
`
`IV. BLUE COAT TRIAL ARGUMENTS AND TESTIMONY (EXS. 2018, 2007, 2027)
`AND BLUE COAT TRIAL EXHIBITS (EXS. 2012, 2014, 2016)
`Finjan’s conclusory statement that Blue Coat trial arguments, testimony, and
`
`exhibits are “admissions by a party opponent” is baseless. A party admission must
`
`be “made by the party” against whom the statement is offered. F.R.E. 801(d)(2).
`
`Since PAN was not a party to the Blue Coat case, statements made during and/or
`
`by parties to that case are inadmissible against PAN.
`
`Finjan invites reversible error by asserting that it can attribute statements
`
`made by Blue Coat and its experts to PAN. (Paper 40 at 9.) To do so would violate
`
`PAN’s due process rights, the Administrative Procedure Act, and established
`
`estoppel and preclusion law. See, e.g., Standard Innovation Corp. v. Lelo, Inc.,
`
`IPR2014-00148, Paper 41 at 13-14 (PTAB Apr. 23, 2015); 5 U.S.C. § 554;
`
`Goldberg v. Kelly, 397 U.S. 254, 267-68 (1970); Blonder-Tongue Labs., Inc. v.
`
`
`
`3
`
`
`
`Petitioner’s Reply
`IPR2015-01974
`
`Univ. of Ill. Found., 402 U.S. 313, 329 (1971). Finjan cites no authority
`
`interpreting this provision as dispensing with a petitioner’s right to due process or
`
`as altering well-established estoppel principles. And while Finjan cites one case
`
`that required 35 petitioners to file as one, that decision does not suggest that PAN
`
`can be held to another party’s litigation positions and outcomes in a separate
`
`proceeding.
`
`Finjan’s argument that these exhibits fall within the public records exception
`
`also fails. A public office record is admissible only if it sets out office activities, a
`
`matter observed while under a legal duty to report, or fact findings from an
`
`authorized investigation. F.R.E. 803(8). A claim construction brief (Ex. 2018),
`
`expert declaration (Ex. 2007), trial testimony (Ex. 2027), and internal Blue Coat
`
`emails (Exs. 2012, 2014, 2016) do not “set out” office activities or matters
`
`observed under a duty to report and are not fact findings from an authorized
`
`investigation. At most, they are disputed evidence with inadmissible hearsay
`
`statements by parties not involved in this proceeding. See F.R.E. 803(8).
`
`Finally, while experts may rely on inadmissible evidence, such reliance does
`
`not make underlying evidence admissible. Brose North Am. v. UUSI, LLC,
`
`IPR2014-00417, Paper 49 at 26 (PTAB July 20, 2015); F.R.E. 703.
`
`V.
`
`BLUE COAT CLAIM CHART (EX. 2048)
`Finjan does not dispute that Exhibit 2048 was drafted by attorneys
`
`4
`
`
`
`Petitioner’s Reply
`IPR2015-01974
`
`
`unqualified to provide expert testimony. (Paper 40 at 12-14.) Finjan argues only
`
`that PAN waived its objections. (Id. at 12.) But PAN objected under FRE 703 to
`
`Finjan’s “made-for-litigation” chart (Paper 23 at 8), and Finjan suffers no prejudice
`
`since supplemental evidence could not cure the objection. See St. Jude Med. v. Bd.
`
`of Regents of Univ. of Mich. IPR2013-00041, Paper 69 at 32 (PTAB May 1, 2014).
`
`Even if a litigation claim chart were sufficient to put Blue Coat on notice
`
`that Finjan practiced the claims, it is not probative of whether Blue Coat knew of
`
`Finjan’s patents when developing the accused products. See F.R.E. 402, 403.
`
`Moreover, the chart is inadmissible hearsay offered to prove that Finjan’s
`
`product embodied the ’633 patent. (Paper 22 at 43.) Finjan’s assertion that the
`
`chart is a public record is baseless for the reasons discussed in Section IV above.
`
`VI. SECURE COMPUTING MATERIALS (EXS. 2037, 2029) & ORDER (EX. 2028)
`Finjan does not contest that exhibit 2029 is hearsay, arguing only that its
`
`expert may still rely on it. (Paper 40 at 14-15.) But expert reliance does not render
`
`the underlying exhibit admissible. (See § IV, supra.) Finjan makes the same
`
`argument for Exhibit 2037, and also asserts that it is a public record. But merely
`
`entering an email chain as a trial exhibit does not bring it within the public records
`
`exception. (Id; F.R.E. 803(8).) Finjan’s attempt to show relevance for all three
`
`exhibits by linking the ’633 patent to Secure Computing is based on inadmissible
`
`hearsay, which is not admissible against PAN as discussed in Section IV above.
`
`
`
`5
`
`
`
`Petitioner’s Reply
`IPR2015-01974
`
`Dated: December 13, 2016
`
`COOLEY LLP
`ATTN: Patent Group
`1299 Pennsylvania Ave., NW, Suite 700
`Washington, DC 20004
`Tel: (703) 456-8000
`Fax: (202) 842-7899
`
`
`
`
`
`
`By:
`
`
`
`Respectfully submitted,
`COOLEY LLP
`
`
`
`/Orion Armon/
`Orion Armon
`Reg. No. 65,421
`
`
`
`6
`
`
`
`Petitioner’s Reply
`IPR2015-01974
`
`
`
`CERTIFICATE OF COMPLIANCE WITH PAGE LIMIT
`Pursuant to 37 C.F.R. § 42.24(d), I certify that this Response complies with
`
`the type-volume limits of 37 C.F.R. § 42.24(c)(2) because it contains 5 pages,
`
`excluding the parts of this Reply that are exempted by 37 C.F.R. § 42.24(a).
`
`
`Dated: December 13, 2016
`
`COOLEY LLP
`ATTN: Patent Group
`1299 Pennsylvania Ave., NW, Suite 700
`Washington, DC 20004
`Tel: (703) 456-8000
`Fax: (202) 842-7899
`
`
`
`
`Respectfully submitted,
`COOLEY LLP
`
`By:
`
`/Orion Armon/
`Orion Armon
`Reg. No. 65,421
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Reply
`IPR2015-01974
`
`
`
`
`
`CERTIFICATE OF SERVICE
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned certifies that on
`
`December 13, 2016, a complete and entire copy of this PETITIONER’S REPLY
`
`IN SUPPORT OF ITS MOTION TO EXCLUDE EVIDENCE was served by
`
`filing this document through the E2E System and via electronic mail upon the
`
`following counsel of record:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Michael T. Rosato
`Andrew S. Brown
`WILSON SONSINI GOODRICH &
`ROSATI
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104-7036
`Phone: (206) 883-2925
`Fax: (206) 883-2699
`mrosato@wsgr.com
`asbrown@wsgr.com
`
`Neil N. Desai (Reg. 69,905)
`WILSON SONSINI GOODRICH &
`ROSATI
`633 West 5th Street, 15th Floor
`Los Angeles, CA 90071-2027
`Phone: (323) 210-2912
`Fax: (866) 974-7329
`ndesai@wsgr.com
`
`
`By:
`
`
`
`/Orion Armon/
`Orion Armon
` Reg. No. 65,421
`
`
`
`James Hannah
`KRAMER LEVIN NAFTALIS &
`FRANKEL LLP
`990 Marsh Road
`Menlo Park, CA 94025
`Phone: (650) 752-1712
`Fax: (650) 752-1812
`jhannah@kramerlevin.com
`
`Jeffrey H. Price
`KRAMER LEVIN NAFTALIS &
`FRANKEL LLP
`1177 Avenue of the Americas
`New York, NY 10036
`Phone: (212) 715-7502
`Fax: (212) 715-8302
`jprice@kramerlevin.com
`
`Michael Kim (Reg. 40,450)
`Finjan, Inc.
`2000 University Ave., Ste. 600
`E. Palo Alto, CA 94303
`Phone: 650.397.9567
`mkim@finjan.com